

# **Cérebro 40+ - A importância da suplementação para atrasar o neuroenvelhecimento.**

**Prof. Dr. Fabrício Assini**

Farmacêutico (UFSC-2000)

Mestre em Psicofarmacologia (UFSC-2005)

Doutor em Psicofarmacologia (UFSC-2011)

Diretor Científico da Escola de Neurosuplementação

$P = \bar{S}$   
 $w = \frac{mgl}{f}$   
 $x = \rho \cos \varphi, y = \rho \sin \varphi$   
 $\rho = \sqrt{x^2 + y^2}$   
 $x - x_0 = 0$   
 $\frac{h}{g - 5m} \rightarrow ?$   
 $\begin{cases} x' = x_0 + mt' \\ y' = y_0 + nt' \\ z' = z_0 + pt' \end{cases}$   
 Formula from's  
 $1) \bar{v} = \frac{t}{t}$   
 $2) v = \frac{r}{t}$   
 $3) T = \frac{v}{T}$   
 $4) T = \frac{2\pi r}{v}$   
 $5) v = \frac{2\pi r}{T}$   
 $6) v = \frac{v}{2\pi r}$   
 $w = BC \omega = 0$   
 $w = DA$   
 $z w = A$   
 $\frac{dp}{p} + \gamma \frac{dv}{v} = 0$   
 $I = \frac{U}{R}$   
 $\frac{2\pi r}{v}$   
 $\downarrow \tau = \text{const}$   
 $\uparrow a = \text{const}$   
 Resistance



O cérebro é o órgão da alma.

**Journal of Diabetes Science and Technology**

Volume 2, Issue 6, November 2008

© Diabetes Technology Society

**REVIEW ARTICLE**

## **Alzheimer's Disease Is Type 3 Diabetes—Evidence Reviewed**

Suzanne M. de la Monte, M.D., M.P.H.<sup>1-3</sup> and Jack R. Wands, M.D.<sup>3</sup>

# **Estamos errados ao chamar o Alzheimer de Diabetes do Tipo 3?**

# COMMENT

**PHYSICS** Explore indirect tests of gravity's quantum behaviour **p.156**

**TECHNOLOGY** A life of Claude Shannon, impish father of the information age **p.159**

**HISTORY** Letters from the Gulag taught science to a toddler **p.160**



**GENETICS** Jennifer Doudna responds to a review of her book **p.162**



KATHERINE FREY/ISTOCK/GETTY IMAGES

The number of people living with Alzheimer's is on the rise — one in ten people aged 65 or over now has the disease.

## Stop Alzheimer's before it starts

Success in the hunt for drugs to halt Alzheimer's disease has remained elusive; it's time to stop the disease before it gets started, urge Eric McDade and Randall J. Bateman.

**I**n 2015, the global cost of Alzheimer's disease was US\$818 billion. That's similar to the gross domestic product of the world's 18th-largest economy. By 2030, the number of people with the disease is expected to rise to more than 70 million worldwide (see 'Staying ahead').

Unless there is a breakthrough in treatment, nearly one in every 2–3 people over 85 will have Alzheimer's. Even those who escape the disease will have at least one close friend or relative who can no longer converse with them, has no recollection of what happened minutes before and is

reliant on round-the-clock care.

Clinical trials have predominantly focused on therapies aimed at treating people who have developed symptoms (memory loss, confusion and difficulties communicating) and begun to lose independence. In the past five years, investigators have started trials at an earlier stage — when memory loss is mild or absent but brain scans reveal the hallmark pathology of amyloid- $\beta$  protein plaques. However, we think that the clock should be turned back even further — to when the signature brain pathology hasn't yet appeared.


An important precedent for such

'primary prevention' is statins. In the early 1980s, these now-widespread medications were shown to lower blood cholesterol in people with a rare genetic disorder that severely elevates it. People with the condition (around 0.005% of the population) typically develop cardiovascular symptoms as adolescents or young adults. Without treatment, they typically die in their 30s<sup>1</sup>. But when statins are given to such people in childhood, the onset of heart disease and stroke is delayed by decades, and lifespan prolonged by between 15 and 30 years.

The search for an Alzheimer's 'statin' is ▶

# STAYING AHEAD


Primary prevention trials would investigate drugs designed to treat Alzheimer's disease before brain pathology, such as amyloid- $\beta$  plaques and tau tangles, or cognitive symptoms develop.



Fonte: Nature (153) vol 547 | 2017

## STAYING AHEAD

Primary prevention trials would investigate drugs designed to treat Alzheimer's disease before brain pathology, such as amyloid- $\beta$  plaques and tau tangles, or cognitive symptoms develop.



**Mantenha-se à frente**

# **Estamos errados ao chamar o Alzheimer de Diabetes do Tipo 3?**

# Estamos errados ao chamar o Alzheimer de Diabetes do Tipo 3?

Sim ou pelo menos colocando o problema numa escala temporal equivocada ou ainda, com foco muito específico.

**Porque prevenir o  
neuroenvelhecimento  
envolve estimular a saúde  
emocional e cognitiva de  
adultos.**

RESEARCH

Open Access



# Association between childhood friendship and cognitive ageing trajectory in later life: evidence from the China Health and Retirement Longitudinal Study (CHARLS)

Jinzhao Xie<sup>1†</sup>, Xiaoyan Fan<sup>2†</sup>, Ping Yin<sup>1</sup>, Jing Gu<sup>1,3,4\*</sup> and Chengwu Yang<sup>5,6</sup>

## Abstract

**Background:** Childhood experience has been suggested to affect cognitive function in later life. However, the association between childhood friendship status and cognitive ageing trajectory in middle-aged and older adults has not been fully assessed. This study examined the association between childhood friendship status and cognitive ageing trajectory and identified factors modifying this association.

**Methods:** We used four waves of data from the China Health and Retirement Longitudinal Study (CHARLS), a national representative longitudinal study of adults aged 45 years or older, 2011–2018. The CHARLS included surveys on childhood friendship and cognitive assessments. Childhood friendship status was categorised as poor, fair, and good. To examine the association between childhood friendship and cognitive ageing trajectory in later life, we applied multilevel linear regression models, and explored potential influences of sociodemographic factors, health status and behaviours, and childhood conditions on this association.

**Results:** Of the 4,350 participants, 1,919 (44.1%) were women. The mean age was  $56.29 \pm 7.80$  years. We found childhood friendship was significantly associated with cognitive ageing trajectory in later life, with a dose–response relationship. After adjusting for covariates, comparing to participants with poor childhood friendships, those with better childhood friendships had lower rates of cognitive decline ( $\beta = 0.12$ , 95% confidence interval [CI]: 0.03 to 0.22 [interaction term of fair friendship and time];  $\beta = 0.19$ , 95% CI: 0.10 to 0.28 [interaction term of good friendship and time]) and higher level of cognitive functions ( $\beta = 0.40$ , 95% CI: 0.22 to 0.58 [fair friendships];  $\beta = 0.61$ , 95% CI: 0.43 to 0.79 [good friendships]). These associations were stronger for those who were female, less educated, and had experienced more adverse childhood experiences.

**Conclusions:** Childhood friendship is associated with cognitive ageing in later life. Enhancing childhood friendships can play an important role to promote healthy ageing in the future.

**Keywords:** Cognitive ageing, Childhood friendship, Multilevel model, China

Current Nutrition Reports

<https://doi.org/10.1007/s13668-019-0276-z>


NUTRITION AND THE BRAIN (J NASSER, SECTION EDITOR)

# Impact of Brain Insulin Signaling on Dopamine Function, Food Intake, Reward, and Emotional Behavior

André Kleinridders<sup>1,2</sup> • Emmanuel N. Pothos<sup>3</sup>



© Springer Science+Business Media, LLC, part of Springer Nature 2019





**Existe envelhecimento  
NORMAL do SNC?**



# HHS Public Access

Author manuscript


*J Neurochem.* Author manuscript; available in PMC 2019 March 01.

Published in final edited form as:

*J Neurochem.* 2018 March ; 144(5): 595–608. doi:10.1111/jnc.14234.

## **Cerebral Blood Flow in Normal Aging Adults: Cardiovascular Determinants, Clinical Implications, and Aerobic Fitness**



**Takashi Tarumi<sup>a,b</sup> and Rong Zhang<sup>a,b,c</sup>**



**Figure 2.**


Association between age and the proportion of cardiac output distributed to the brain

( $n=139$ ). The CCRI represents the cerebral blood flow to cardiac output ratio index. Panel A shows the linear decline of CCRI with increasing age ( $CCRI = -0.127\% \times \text{age} + 22.72\%$  with  $R^2=0.13$ ,  $P < 0.001$ ). Panel B shows the association between age and CCRI in men and women separately ( $P < 0.001$  for age group,  $P < 0.001$  for sex, and  $P = 0.26$  for age and sex interaction). Young = 21–45 years; middle age = 45–65 years; and old = 66–80 years. Error bars




**Figure 2.**

Association between age and the proportion of cardiac output distributed to the brain (n=139). The CCRI represents the cerebral blood flow to cardiac output ratio index. Panel A shows the linear decline of CCRI with increasing age ( $CCRI = -0.127\% \times \text{age} + 22.72\%$  with  $R^2 = 0.13$ ,  $P < 0.001$ ). Panel B shows the association between age and CCRI in men and women separately ( $P < 0.001$  for age group,  $P < 0.001$  for sex, and  $P = 0.26$  for age and sex interaction). Young=21–45 years; middle age=45–65 years; and old=66–80 years. Error bars



**Figure 5. Life-span trajectories of volumetric reductions**  
Cross-sectional estimates of adult life-span trajectories of total cerebral cortex volume and total hippocampal volume. Volume is expressed in units of standard deviations. Data from (Fjell et al., 2013c).

Fonte: *Prog Neurobiol.* 2014 June ; 117: 20–40.  
doi:10.1016/j.pneurobio.2014.02.004



Fonte: *Adv Pharmacol.* 2012 ; 64: 327–371.  
doi:10.1016/B978-0-12-394816-8.00010-6.


**Existe uma atrofia normal durante o envelhecimento do cérebro**, essa diminuição acontece tanto na substância cinzenta quanto branca e também está associada com o crescimento dos ventrículos. Drayer BP. Imaging of the aging brain. Part I Normal findings. Radiology. 1988; 166:785–796.

- Análises histológicas sugerem que a atrofia esteja **relacionada com a regressão de dendritos** e morte neuronal. Dumitriu D, J Neurosci. 2010; 30:7507–7515



*“Cada neurônio faz em média 10.000 sinapses. Podendo chegar ao extremo de 200.000 nos dendritos das células de Purkinje do cerebelo”*

(Roberto Lent, 100 bilhões de neurônios).



Ramón y Cajal, S. Degeneration and Regeneration of the Nervous System (Trans. Day, R. M., from the 1913 Spanish edn) (Oxford Univ. Press, London, 1928).



*“Cada neurônio faz em média 10.000 sinapses. Podendo chegar ao extremo de 200.000 nos dendritos das células de Purkinje do cerebelo”*

(Roberto Lent, 100 bilhões de neurônios).

**E dai?!**

Psychiatry Research: Neuroimaging 266 (2017) 1–9



Contents lists available at ScienceDirect

## Psychiatry Research: Neuroimaging

journal homepage: [www.elsevier.com/locate/psychresns](http://www.elsevier.com/locate/psychresns)



### Frontal and subcortical grey matter reductions in PTSD

Daniel C.M. O'Doherty<sup>a,\*</sup>, Ashleigh Tickell<sup>a</sup>, Will Ryder<sup>a</sup>, Charles Chan<sup>a</sup>, Daniel F. Hermens<sup>a</sup>,  
Maxwell R. Bennett<sup>a</sup>, Jim Lagopoulos<sup>b</sup>



# Brain Atrophy in Multiple Sclerosis

## Clinical Relevance and Technical Aspects

Jaume Sastre-Garriga, MD, PhD<sup>a,\*</sup>, Deborah Pareto, PhD<sup>b,c</sup>,  
Àlex Rovira, MD<sup>b,c</sup>

Neuroimag Clin N Am ■ (2017) ■-■

<http://dx.doi.org/10.1016/j.nic.2017.01.002>

1052-5149/17/© 2017 Elsevier Inc. All rights reserved.

*Psychological Medicine* (2015), 45, 1931–1944. © Cambridge University Press 2015  
doi:10.1017/S0033291714003055

ORIGINAL

# Depression, depressive symptoms, and rate of hippocampal atrophy in a longitudinal cohort of older men and women


# GENÉTICA

G1, G2, G3

Epigenética

# AMBIENTE

Estresse,  
traumas,  
relações  
interpessoais...



Tristeza e sentimento de culpa;

Anedonia;

Agitação/lentidão;

Tendências suicidas;

Alterações de sono;

Atenção e foco;

Aprendizado e memória


# Por onde começar?

**3 passos  
essenciais  
para ajustar a  
neuroquímica  
e promover  
saúde  
emocional e  
cognitiva**

**Esteja atento para os  
fatores de risco durante a  
anamnese;**

**Garanta a síntese de ATP;**

**Pense de maneira  
integrativa.**



**Fig. 1 | Risk and protective factors for dementia and Alzheimer disease across the lifespan.** Some factors can differentially affect the risk of dementia and Alzheimer disease in an individual depending on the time of exposure within the life course. For example, hypertension, obesity and dyslipidaemia increase dementia risk when a person is exposed during midlife. By contrast, other factors such diet affect risk across the lifespan. CAIDE, Cardiovascular Risk Factors, Aging and Dementia.


Concepts proposed to explain mechanisms associated with protection against dementia:

- Brain reserve
- Cognitive reserve

Physical, cognitive and social activity

Education





**Table 1**


Current evidence for preventive strategies, targeting risk and protective factors, and the underlying biological mechanisms.

Preventive strategies	Risk and protective factors	Biological mechanisms				
		Neurodegeneration	Brain resilience	Vascular damage	Inflammation	Oxidative stress
Targeting the body to protect the brain	Systemic and cerebral atherosclerosis	c		a	a	c
	Atrial fibrillation	c		a	b	c
	Heart failure	c		a	b	c
	Ischemic heart disease	c		a	b	c
	Mid-life hypertension	b		a	b	c
	Diabetes	b		a	b	b
	Mid-life obesity	c				
Interventions to counteract brain aging	High education		b			
	Work complexity		b			c (Reduced)
	Leisure-time mentally, socially and physically stimulating activities		b	b (Reduced)	b (Reduced)	c (Reduced)
Lifespan health promotion to reduce dementia risk	Physical inactivity	b	b	a	b	c
	Smoking	c		a	b	c
	Excessive alcohol consumption	c		a	b	c
	Unhealthy/imbalanced diet	c		a	b	c

<sup>a</sup> Strong evidence (i.e. evidence from meta-analyses, RCTs, well designed cohort studies with consistent findings).

<sup>b</sup> Emerging evidence (i.e. less consistent findings).

<sup>c</sup> Limited evidence (i.e. limited number of studies).



Fonte: Fotuhi, M. *et al.* *Nat. Rev. Neurol.* 8, 189–202 (2012); [doi:10.1038/nrneurol.2012.27](https://doi.org/10.1038/nrneurol.2012.27)

## The CAIDE dementia risk score

Risk factor		Points
Age	<47 years	0
	47–53 years	3
	>53 years	4
Education	≥10 years	0
	7–9 years	2
	<7 years	3
Sex	Female	0
	Male	1
Blood pressure	≤140 mmHg	0
	>140 mmHg	2
BMI	≤30 kg/m <sup>2</sup>	0
	>30 kg/m <sup>2</sup>	2
Total cholesterol	≤6.5 mmol/l	0
	>6.5 mmol/l	2
Physical activity	Yes	0
	No	1




Fig. 2 | **CAIDE risk score.** The Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score enables the prediction of the later risk of dementia on the basis of the risk factor profile present in midlife (age 40–65 years).

# Montreal Cognitive Assessment (MOCA) test

Valores abaixo de 26 indicam prejuízo cognitivo leve.

MONTREAL COGNITIVE ASSESSMENT (MOCA)  
Versão Experimental Brasileira

Nome: \_\_\_\_\_ Data de nascimento: \_\_\_/\_\_\_/\_\_\_  
Escolaridade: \_\_\_\_\_ Data de avaliação: \_\_\_/\_\_\_/\_\_\_  
Sexo: \_\_\_\_\_ Idade: \_\_\_\_\_



VISUOESPACIAL / EXECUTIVA		Copiar o cubo		Desenhar um RELÓGIO (onze horas e dez minutos) (3 pontos)		Pontos
		<input type="checkbox"/>		<input type="checkbox"/>		<input type="checkbox"/>
		Contorno		Números		Ponteiros
		[ ]		[ ]		[ ]
<b>NOMEAÇÃO</b>						
						<input type="checkbox"/>
		[ ]		[ ]		[ ]
<b>MEMÓRIA</b>						
Leia a lista de palavras, O sujeito de repeti-la, faça duas tentativas. Evocar após 5 minutos.		Rosto	Veludo	Igreja	Margarida	Vermelho
1ª tentativa						
2ª tentativa						
Sem Pontuação						
<b>ATENÇÃO</b>						
Leia a sequência de números (1 número por segundo)		O sujeito deve repetir a sequência em ordem direta [ ] 2 1 8 5 4		O sujeito deve repetir a sequência em ordem indireta [ ] 7 4 2		<input type="checkbox"/>
		[ ]		[ ]		[ ]
Leia a série de letras. O sujeito deve bater com a mão (na mesa) cada vez que ouvir a letra "A". Não se atribuem pontos se ≥ 2 erros.						
		[ ]		[ ]		[ ]
		F B A C M N A A J K L B A F A K D E A A A J A M O F A A B				
Subtração de 7 começando pelo 100 [ ] 93 [ ] 86 [ ] 79 [ ] 72 [ ] 65						
		[ ]		[ ]		[ ]
		4 ou 5 subtrações corretas: 3 pontos; 2 ou 3 corretas 2 pontos; 1 correta 1 ponto; 0 correta 0 ponto				
<b>LINGUAGEM</b>						
Repetir: Eu somente sei que é João quem será ajudado hoje. [ ]		O gato sempre se esconde embaixo do Sofá quando o cachorro está na sala. [ ]				<input type="checkbox"/>
		[ ]		[ ]		[ ]
Fluência verbal: dizer o maior número possível de palavras que comecem pela letra F (1 minuto). [ ] _____ (N ≥ 11 palavras)						
		[ ]		[ ]		[ ]
<b>ABSTRAÇÃO</b>						
Semelhança p. ex. entre banana e laranja = fruta [ ]		trem - bicicleta [ ]		relógio - régua		<input type="checkbox"/>
		[ ]		[ ]		[ ]
<b>EVOCAÇÃO TARDIA</b>						
Deve recordar as palavras SEM PISTAS		Rosto	Veludo	Igreja	Margarida	Vermelho
		[ ]	[ ]	[ ]	[ ]	[ ]
Pontuação apenas para evocação SEM PISTAS						
<b>OPCIONAL</b>						
Pista de categoria						
Pista de múltipla escolha						
<b>ORIENTAÇÃO</b>						
[ ] Dia do mês [ ] Mês [ ] Ano [ ] Dia da semana [ ] Lugar [ ] Cidade						<input type="checkbox"/>
		[ ]		[ ]		[ ]
TOTAL Adicionar 1 pt se ≤ 12 anos de escolaridade <input type="checkbox"/>						
		[ ]		[ ]		[ ]

## Linha do tempo para o diagnóstico do prejuízo cognitivo:

1 – Declínio cognitivos subjetivos (“normais” ao envelhecimento);

*Atividade cognitiva menos eficiente; Desbalanço fisiológico;*

2 – Prejuízo cognitivo leve;

*Desequilíbrio metabólicos; Início da neurodegeneração; Depressão, ansiedade, fadiga crônicas;*

3) Demências;

*Prejuízo das atividades diárias causadas pela neurodegeneração ou demência metabólica.*

## Fatores de risco para a saúde emocional e cognitiva:

- Sedentarismo, baixa escolaridade, falta de estímulos cognitivos, tabagismo, má alimentação;
- Abuso de álcool (+ de 14 doses para homens ou + 7 doses mulheres por semana)
- Hipertensão, obesidade, dislipidemia, Diabetes
- Depressão
- Polimorfismo APOE4
- Aterosclerose sistêmica e cerebral
- Fibrilação atrial, falência cardíaca, Doença isquêmica coronária
- Apneia obstrutiva do sono
- Traumas encefálicos
- MOCA teste abaixo de 26
- CAIDE escore acima de 12

**3 passos  
essenciais  
para ajustar a  
neuroquímica  
e promover  
saúde  
emocional e  
cognitiva**

Esteja atento para os  
fatores de risco durante a  
anamnese;

Garanta a síntese de ATP;

Pense de maneira  
integrativa.




**2% do peso corporal**

**20% do débito cardíaco**



**20% do consumo de ATP/diário**

Fonte: Cells **2021**, 10, 2531.  
<https://doi.org/10.3390/cells10102531>

# O cérebro consome 20% do ATP diário



Distribuição do consumo energético no cérebro.



Fonte: Nat Rev Drug Discov. 2020 September ; 19(9): 609–633. doi:10.1038/s41573-020-0072-x.

Molecular Psychiatry

[www.nature.com/mp](http://www.nature.com/mp)

**EXPERT REVIEW**

 Check for updates

# Schizophrenia: a disorder of broken brain bioenergetics

Nicholas D. Henkel <sup>1</sup>✉, Xiajoun Wu<sup>1</sup>, Sinead M. O'Donovan <sup>1</sup>, Emily A. Devine<sup>1</sup>, Jessica M. Jiron<sup>1</sup>, Laura M. Rowland<sup>2</sup>, Zoltan Samyai <sup>3</sup>, Amy J. Ramsey <sup>4</sup>, Zhexing Wen <sup>5</sup>, Margaret K. Hahn <sup>6</sup> and Robert E. McCullumsmith<sup>1,7</sup>

© The Author(s), under exclusive licence to Springer Nature Limited 2022

**Quanta energia gasta o cérebro de alguém que pensa demais?**

[nature](#) > [news](#) > article

NEWS | 11 August 2022

# Why thinking hard makes us feel tired

**Difficult tasks can lead to build-up of a signalling molecule in the brain, triggering fatigue.**


[Heidi Ledford](#)

Para ir além, veja: Wiehler, A., Branzoli, F., Adanyeguh, I., Mochel, F. & Pessiglione, M. *Curr. Biol.* <https://doi.org/10.1016/j.cub.2022.07.010> (2022).

# Suplementação Neuroenergética:

- **Creatina 3-6g/dia**
- **Mg (quelato) 200-350mg/dia**
- **Coenzima Q10 100-300mg/dia**
- **Hexanicotinato de Inositol 200-600mg/dia**
- **NAC 600-1200 mg/dia**
  
- **Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM**

**Divididos em 2-3 tomadas diárias**




**Table 1.** Summary of human studies (excluding CCDS) describing low tissue creatine levels.

Pathology	Refs.
Autism spectrum disorder	[40–45]
Concussion and mild traumatic brain injury	[13,46]
Multiple sclerosis	[47–51]
Gyrate atrophy of the choroid and retina	[15,52]
Post-viral fatigue syndrome	[53,54]
Primary and secondary brain tumors	[17,18]
Neuromuscular disease	[19]
Facioscapulohumeral muscular dystrophy	[20]
Dilated cardiomyopathy	[21,24,25]
Aortic valve disease	[22]
Heart transplantation	[23]
Coronary disease	[26]
Chronic obstructive pulmonary disease	[27,28]
Lung cancer	[29]
Pancreatic cancer	[30]
Hepatitis C	[31]
Chronic HIV infection	[32]
Infant malnutrition	[33]

Fonte: Ostojic, S.M. Low Tissue Creatine: A Therapeutic Target in Clinical Nutrition.

Nutrients **2022**, *14*, 1230.  
<https://doi.org/10.3390/nu14061230>

# Transporte da creatina para o SNC




Fonte: Nutrients **2021**, 13, 586.

<https://doi.org/10.3390/nu13020586>

# A relação entre ATP e Mg<sup>2+</sup>

- A forma ativa do ATP é um complexo com Mg<sup>2+</sup> ;
- Existe, no citoplasma de uma célula normal, uma relação 1:1 nas concentrações de ATP:Mg;
- Os complexos de Mg<sup>2+</sup> com os nucleosídeos trifosfatos são substratos para todas as enzimas dependentes de NTPs;
- Outros NTPs: guanossina trifosfato (GTP), uridina trifosfato (UTP) e citidina trifosfato (CTP).




Estrutura do complexo ATP-miosina em *Dictyostelium discoideum*.

# Suplementação Neuroenergética:

- Creatina 3-6g/dia
- Mg (quelato) 200-350mg/dia
- **Coenzima Q10 100-300mg/dia**
- **Hexanicotinato de Inositol 200-600mg/dia**
- **NAC 600-1200 mg/dia**
  
- **Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM**

**Divididos em 2-3 tomadas diárias**




Fonte: Qi G, Mi Y and Yin F (2020) Cellular Specificity and Inter-cellular Coordination in the Brain Bioenergetic System: Implications for Aging and Neurodegeneration. *Front. Physiol.* 10:1531. doi: 10.3389/fphys.2019.01531

**A glicólise não é uma via importante para a geração de piruvato em neurônios;**

**O lactato proveniente do astrócito é uma importante fonte de piruvato para a formação de acetil-CoA;**

**A principal fonte de ATP é a fosforilação oxidativa porque neurônios fazem pouca beta-oxidação;**




Fonte: Clinical Nutrition 38 (2019) 982e995

# Suplementação Neuroenergética:


- **Creatina 3-6g/dia**
- **Mg (quelato) 200-350mg/dia**
- **Coenzima Q10 100-300mg/dia**
- **Hexanicotinato de Inositol 200-600mg/dia**
- **NAC 600-1200 mg/dia**
  
- **Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM**

**Divididos em 2-3 tomadas diárias**

# Vias de síntese do NAD



Fonte: doi:  
10.1210/js.2017-00092 |  
Journal of the Endocrine  
Society | 816–835



Fonte: Nature Reviews, **Neurology**,  
<https://doi.org/10.1038/s41582-019-0244-7>


**Perceba o **NAD** como uma  
molécula chave na **relação  
núcleo x mitocôndria X  
inflamação.****

# Suplementação Neuroenergética:

- **Creatina 3-6g/dia**
- **Mg (quelato) 200-350mg/dia**
- **Coenzima Q10 100-300mg/dia**
- **Hexanicotinato de Inositol 200-600mg/dia**
- **NAC 600-1200 mg/dia**
  
- **Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM**

**Divididos em 2-3 tomadas diárias**

# Impacto do envelhecimento sobre o metabolismo da glicose no cérebro



**A via das pentoses é relevante na bioenergética neuronal e fundamental para a formação de NADPH.**

**Este último, essencial para a formação de GLUTATIONA REDUZIDA (o principal antioxidante de neurônios);**

# Suplementação Neuroenergética:

- Creatina 3-6g/dia
- Mg (quelato) 200-350mg/dia
- Coenzima Q10 100-300mg/dia
- Hexanicotinato de Inositol 200-600mg/dia
- NAC 600-1200 mg/dia
  
- Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM

**Divididos em 2-3 tomadas diárias**

B




Figure 1. Bioenergetic substrate and catalytic compensatory adaptations to sustain metabolic demand of the brain



# Links Between Metabolic and Structural Changes in the Brain of Cognitively Normal Older Adults: A 4-Year Longitudinal Follow-Up

Christian-Alexandre Castellano<sup>1\*</sup>, Carol Hudon<sup>2,3</sup>, Etienne Croteau<sup>1,4</sup>, Mélanie Fortier<sup>1</sup>, Valérie St-Pierre<sup>1</sup>, Camille Vandenberghe<sup>1</sup>, Scott Nugent<sup>2</sup>, Sébastien Tremblay<sup>5</sup>, Nancy Paquet<sup>6</sup>, Martin Lepage<sup>5,6,7</sup>, Tamàs Fülöp<sup>1,8</sup>, Éric E. Turcotte<sup>5,6,7</sup>, Isabelle J. Dionne<sup>1,9</sup>, Olivier Potvin<sup>2</sup>, Simon Duchesne<sup>2,10</sup> and Stephen C. Cunnane<sup>1,4,8</sup>

We aimed to longitudinally assess the relationship between changing brain energy metabolism (glucose and acetoacetate) and cognition during healthy aging. Participants aged  $71 \pm 5$  year underwent cognitive evaluation and quantitative positron emission tomography (PET) and magnetic resonance imaging (MRI) scans at baseline ( $N = 25$ ) and two ( $N = 25$ ) and four ( $N = 16$ ) years later. During the follow-up, the rate constant for brain extraction of glucose ( $K_{glc}$ ) declined by 6%–12% mainly in the temporo-parietal lobes and cingulate gyri ( $p \leq 0.05$ ), whereas brain acetoacetate extraction ( $K_{acac}$ ) and utilization remained unchanged in all brain regions ( $p \geq 0.06$ ). Over the 4 years, cognitive results remained within the normal age range but an age-related decline was observed in processing speed.  $K_{glc}$  in the caudate was directly related to performance on several cognitive tests ( $r = +0.41$  to  $+0.43$ , all  $p \leq 0.04$ ). Peripheral insulin resistance assessed by the homeostasis model assessment of insulin resistance (HOMA-IR) was significantly inversely related to  $K_{glc}$  in the thalamus ( $r = -0.44$ ,  $p = 0.04$ ) and in the caudate ( $r = -0.43$ ,  $p = 0.05$ ), and also inversely related to executive function, attention and processing speed ( $r = -0.45$  to  $-0.53$ , all  $p \leq 0.03$ ). We confirm in a longitudinal setting that the age-related decline in  $K_{glc}$  is directly associated with declining performance on some tests of cognition but does not significantly affect  $K_{acac}$ .

**Tanto em momentos de demandas metabólicas aumentadas quanto com envelhecimento neuronal os corpos cetônicos passam a ter um papel importante na geração de ATP em neurônios.**

**Com a exaustão dos corpos cetônicos leva a **degradação da bainha de mielina** para o fornecimento de ácidos graxos para a beta-oxidação.**



# HHS Public Access

Author manuscript

*Ageing Res Rev.* Author manuscript; available in PMC 2021 March 01.



Published in final edited form as:


*Ageing Res Rev.* 2020 March ; 58: 101001. doi:10.1016/j.arr.2019.101001.

## **Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies**


**Konstantinos I. Avgerinos<sup>1</sup>, Josephine M. Egan<sup>2</sup>, Mark P. Mattson<sup>1</sup>, Dimitrios Kapogiannis<sup>1,\*</sup>**

<sup>1</sup>Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, US


<sup>2</sup>Laboratory of Clinical Investigations, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, US

**Figure 5B.**

Forest plot showing cognitive performance (measured with Standardized Mean Difference derived from changes on (i) the Spanish version of MMSE in Yang et al study and (ii) ADAS-Cog for the rest studies). Results from meta-analysis of 4 Randomized Controlled Trials, using Continuous Random-Effects Model. Note that as with ADAS-Cog scale, negative changes here also indicate cognitive improvement



Fonte: Nat Rev Drug Discov.  
2020 September ; 19(9): 609–  
633. doi:10.1038/s41573-020-  
0072-x.



Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM

**FIGURE 1** Whole-brain white matter tractograms from a sample participant in the ketogenic medium chain triglyceride (kMCT) group before (PRE) and after (POST) the 6-month intervention. Streamlines are colored according to their acetoacetate metabolic rate ( $\mu\text{mol/g/min}$ ). Subsets of 10,000 streamlines per whole-brain tractogram are shown.

# Suplementação Neuroenergética:

- Creatina 3-6g/dia
- Mg (quelato) 200-350mg/dia
- Coenzima Q10 100-300mg/dia
- Hexanicotinato de Inositol 200-600mg/dia
- NAC 600-1200 mg/dia
- Solução composta pela associação de C8 (60%) e C10 (40%) fornecendo 30g/dia dos TCM

**Divididos em 2-3 tomadas diárias**

**3 passos  
essenciais  
para ajustar a  
neuroquímica  
e promover  
saúde  
emocional e  
cognitiva**

**Esteja atento para os  
fatores de risco durante a  
anamnese;**

**Garanta a síntese de ATP;**

**Pense de maneira  
integrativa.**


# GENÉTICA

G1, G2, G3

Epigenética

# AMBIENTE

Estresse,  
traumas,  
relações  
interpessoais...



Tristeza e sentimento de culpa;

Anedonia;

Agitação/lentidão;

Tendências suicidas;

Alterações de sono;

Atenção e foco;

Aprendizado e memória



○ **Suplemento é o vento a favor** para quem já entendeu a **necessidade de pedalar!**

ARTICLE

# Nutrients and bioactives in green leafy vegetables and cognitive decline

Prospective study

Martha Clare Morris, ScD, Yamin Wang, PhD, Lisa L. Barnes, PhD, David A. Bennett, MD, Bess Dawson-Hughes, MD, and Sarah L. Booth, PhD


*Neurology*® 2018;90:e214-e222. doi:10.1212/WNL.0000000000004815

**Correspondence**

Dr. Morris

Martha\_C\_Morris@rush.edu

**Figure** Rate of decline in global cognitive score for the top and the lowest quintile of intake of green leafy vegetables



Rate of decline in global cognitive score for the top quintile of intake of green leafy vegetables (median 1.3 servings/d) and the lowest quintile of intake (median 0.09 servings/d) based on mixed models adjusted for age, sex, education, energy intake, participation in cognitive activities, physical activity, smoking, and alcohol consumption in 960 Rush Memory and Aging Project participants, 2004–2014.

**O consumo diário de verdes folhosos (equivalente a uma xícara por dia) irá deixar seu cérebro 10 anos mais jovem.**

Fonte: Neurology® 2018;90:e214-e222. doi:10.1212/WNL.0000000000004815



*nutrients*



*Article*

# A High Polyphenol Diet Improves Psychological Well-Being: The Polyphenol Intervention Trial (PPhIT)

Fonte: Nutrients **2020**, 12, 2445; doi:10.3390/nu12082445





Figure 1. CONSORT diagram summarizing flow of participants through the study.

Table 3. Changes in mood, self-esteem, body image and quality of life indicators according to the Polyphenol Intervention Trial (PPhIT) study group allocation.

	Low Polyphenol Diet ( $n_{\max} = 50$ )				High Polyphenol Diet ( $n_{\max} = 49$ )				
	Week 0 <sup>1</sup>	Week 12	Median Change (IQR) <sup>2</sup>	Within Group Change ( $p$ Value) <sup>3</sup>	Week 0 <sup>1</sup>	Week 12	Median Change (IQR) <sup>2</sup>	Within Group Change ( $p$ Value) <sup>3</sup>	Between Group Change ( $p$ Value) <sup>4</sup>
<b>BDI-II *</b>	6.0 (2.0, 12.5)	7.0 (2.0, 11.0)	0.2 (-1.5, 1.9)	0.98	6.0 (3.0, 12.0)	2.0 (0.0, 6.0)	-3.4 (-5.4, -1.5)	<0.001	0.01
<b>DASS-21 **</b>									
Depression <sup>5</sup>	2.0 (0.0, 12.0)	6.0 (0.0, 10.5)	0 (-2.0, 6.0)	0.29	2.0 (0.0, 10.0)	0.0 (0.0, 6.0)	0 (-2.0, 0.0)	0.53	0.56
Anxiety <sup>5</sup>	4.0 (2.0, 9.0)	2.0 (0.0, 8.0)	0.0 (-3.0, 3.0)	0.86	4.0 (0.0, 10.0)	2.0 (0.0, 6.0)	0.0 (-2.0, 0.0)	0.16	0.8
Stress <sup>5</sup>	7.0 (2.0, 12.5)	8.0 (0.0, 16.0)	0 (-2.0, 4.0)	0.76	6.0 (2.0, 14.0)	4.0 (0.0, 10.0)	-2.0 (-6.0, 2.0)	0.05	0.14
<b>PANAS ***</b>									
Positive affect	29.9 (8.3)	30.4 (9.8)	0.5 (-1.5, 2.5)	0.63	33.0 (6.8)	35.2 (7.4)	2.2 (0.3, 4.1)	0.03	0.21
Negative affect	11.0 (10.0, 13.0)	11.0 (10.0, 13.0)	0.0 (-1.5, 1.5)	0.56	12.0 (10.0, 15.0)	10.0 (10.0, 14.0)	0.0 (-1.0, 0.5)	0.68	0.99
<b>Rosenberg Self-Esteem Score †</b>	26.0 (25.0, 28.0)	26.0 (25.0, 28.0)	0.0 (-2.0, 2.0)	0.74	26.0 (25.0, 27.0)	27.0 (24.0, 27.0)	0.0 (-2.0, 2.0)	0.68	0.53
<b>MBSRQ-AS ††</b>									
Appearance Evaluation	2.9 (2.4, 3.5)	3.0 (2.4, 3.6)	0.0 (-0.3, 0.4)	0.27	3.0 (2.5, 3.4)	3.1 (2.7, 3.6)	0.1 (-0.3, 0.4)	0.15	0.76
Appearance Orientation	3.0 (2.5, 3.7)	3.0 (2.5, 3.7)	0.0 (-0.3, 0.2)	0.35	3.2 (2.8, 3.5)	3.3 (2.9, 3.8)	0.2 (-0.2, 0.4)	0.16	0.1
Body areas Satisfaction	3.0 (2.7, 3.4)	3.3 (2.4, 3.7)	0.2 (-0.1, 0.4)	0.03	3.1 (2.7, 3.6)	3.3 (2.8, 3.8)	0.2 (-0.1, 0.3)	0.02	0.71
Overweight Preoccupation	2.3 (1.8, 2.8)	2.4 (1.8, 2.8)	0.0 (-0.3, 0.5)	0.87	2.5 (1.8, 3.3)	2.6 (1.8, 3.2)	0.0 (-0.5, 0.3)	0.45	0.72
Self-classified Weight <sup>1</sup>	4.0 (3.4, 4.0)	4.0 (3.0, 4.0)	0.0 (0.0, 0.0)	0.08	4.0 (3.5, 4.0)	4.0 (3.5, 4.0)	0.0 (0.0, 0.0)	0.43	0.5
<b>SF-36 †††</b>									
Physical Functioning	90 (75.0, 97.5)	90 (81.3, 100.0)	0 (0.0, 10.0)	0.07	95 (80.0, 100.0)	95 (85.0, 100.0)	0 (-5.0, 10.0)	0.15	0.44
Role limitations—physical health	100 (37.5, 100.0)	100 (37.5, 100.0)	0 (0.0, 25.0)	0.45	100 (75.0, 100.0)	100 (100.0, 100.0)	0 (0.0, 0.0)	<0.001	0.61
Pain	80 (47.5, 100.0)	80 (46.3, 100.0)	0 (-10.0, 10.0)	0.64	90 (60.0, 90.0)	90 (70.0, 100.0)	0 (-10.0, 22.5)	0.2	0.51
General health	65 (45.0, 75.0)	60 (50.0, 75.0)	0 (-10.0, 10.0)	0.47	65 (50.0, 75.0)	75 (65.0, 85.0)	10 (-5.0, 20.0)	<0.001	0.03
Physical health component	210.5 (168.5, 223.1)	200.9 (172.9, 217.2)	-6.4 (-17.0, 4.2)	0.09	213.2 (189.6, 225.1)	216.6 (201.4, 225.3)	2.2 (-8.1, 15.4)	0.2	0.04
Role limitations—emotional health	100 (100.0, 100.0)	100 (100.0, 100.0)	0 (0.0, 0.0)	0.99	100 (100.0, 100.0)	100 (100.0, 100.0)	0 (0.0, 0.0)	0.1	0.85
Energy/fatigue	55 (40.0, 72.5)	60 (45.0, 70.0)	5 (-5.0, 10.0)	0.39	60 (50.0, 80.0)	70 (60.0, 80.0)	5 (0.0, 20.0)	<0.001	0.02
Emotional well-being	76 (64.0, 84.0)	80 (62.0, 86.0)	0 (-8.0, 8.0)	0.73	80 (60.0, 88.0)	84 (72.0, 92.0)	4 (0.0, 16.0)	0	0.01
Social functioning	100 (75.0, 100.0)	100 (75.0, 100.0)	0 (-6.3, 0.0)	0.97	100 (75.0, 100.0)	100 (100.0, 100.0)	0 (0.0, 25.0)	0.02	0.08
Mental health component	209.1 (176.8, 222.3)	197.9 (175.0, 217.2)	-4.0 (-26.6, 8.1)	0.04	208 (181.4, 226.0)	218.3 (201.4, 226.8)	1.9 (-6.9, 19.1)	0.09	0.01

**6 porções de frutas/vegetais ao dia  
(sendo uma porção de “berries” +  
50g de chocolate 70% cacau por 2  
meses exerceram efeito  
significativos sobre a saúde mental,  
bem estar e fadiga/energia.**





**Figure 6.**

Comparison of cerebral blood flow (CBF) among endurance Masters Athletes (MA, n=10), sedentary elderly adults (SE, n=10), and young control subjects (YC, n=9). (A) Brain regions showing greater CBF in MA compared with SE ( $P < 0.005$ , cluster size=250). These voxels are located in the posterior cingulate cortex and precuneus. (B) Relative CBF (normalized against whole-brain value) in the cluster highlighted in (A). (C) Absolute CBF in the cluster highlighted in (A). CBF was measured by arterial spin labeling using MRI.

# Why Loneliness Is Hazardous to Your Health

New research suggests that chronic loneliness can cause changes in the cardiovascular, immune, and nervous systems



**Unrewarding.** Lonely people take less enjoyment from social interactions and exhibit less activity (blue) in the ventral striatum.

14 JANUARY 2011 VOL 331 **SCIENCE** [www.sciencemag.org](http://www.sciencemag.org)

*Published by AAAS*

# Solidão:

**Desconforto** gerado devido a  
uma **discrepância** entre as  
**relações** sociais **existentes** e  
as **relações** sociais **desejadas**.

Fonte: Lam et al., Neuropsychopharmacology (2021) 46:1873–1887;  
<https://doi.org/10.1038/s41386-021-01058-7>

**E se a solidão  
fosse encarada  
como a fome e a  
sede da alma?**



*Nat Neurosci.* 2020 December ; 23(12): 1597–1605. doi:10.1038/s41593-020-00742-z.

## **Acute social isolation evokes midbrain craving responses similar to hunger**





**Livia Tomova<sup>1,✉</sup>, Kimberly L. Wang<sup>1</sup>, Todd Thompson<sup>1</sup>, Gillian A. Matthews<sup>2</sup>, Atsushi Takahashi<sup>3</sup>, Kay M. Tye<sup>2</sup>, Rebecca Saxe<sup>1,3,4</sup>**

<sup>1</sup>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.

<sup>2</sup>Salk Institute for Biological Studies, La Jolla, CA, USA.

<sup>3</sup>McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

<sup>4</sup>Center for Brains, Minds and Machines, Massachusetts Institute of Technology, Cambridge, MA, USA.



Fonte: Nat Neurosci.  
2020 December ; 23(12):  
1597–1605.  
doi:10.1038/s41593-020-  
00742-z.



JAMA Psychiatry. 2021 Jun; 78(6): 1–7.

PMCID: PMC7903319

Published online 2021 Feb 23. doi: 10.1001/jamapsychiatry.2021.0113:

PMID: [33620417](#)

10.1001/jamapsychiatry.2021.0113

## Effect of Layperson-Delivered, Empathy-Focused Program of Telephone Calls on Loneliness, Depression, and Anxiety Among Adults During the COVID-19 Pandemic


A Randomized Clinical Trial


[Maninder K. Kahlon](#), PhD,<sup>✉1</sup> [Nazan Aksan](#), PhD,<sup>1</sup> [Rhonda Aubrey](#), MHI,<sup>1</sup> [Nicole Clark](#), MBA,<sup>1</sup>

[Maria Cowley-Morillo](#),<sup>1</sup> [Elizabeth A. Jacobs](#), MD, MAPP,<sup>1,2</sup> [Rhonda Mundhenk](#), JD, MPH,<sup>3</sup> [Katherine R. Sebastian](#), RN, MPH,<sup>1</sup> and [Steven Tomlinson](#), PhD<sup>4</sup>



Sixteen callers, aged 17 to 23 years, were briefly trained in empathetic conversational techniques. Each called 6 to 9 participants over 4 weeks daily for the first 5 days, after which clients could choose to drop down to fewer calls but no less than 2 calls a week





**Box Plots of Changes in Loneliness, Depression, Anxiety, and General Mental Health Over 4 Weeks in the Intervention and Control Arms**

**Em resumo...**

**Quando pensamos em saúde mental, estar ou pelo menos fazer-se presente, também é terapêutico.**

Fabrício Assini  
@fabriciossini